Search Results
Your search for ,New matches 16916 pages
Showing 15001 - 15050First Winners of Tri-Institutional Breakout Awards Announced
Six young scientists at Memorial Sloan Kettering Cancer Center, Rockefeller University, and Weill Cornell Medical College have been named the inaugural winners of a new prize established to recognize postdoctoral investigators in the life sciences. The Tri-Institutional Breakout Awards for Junior...
The Pediatric Fitness Program: A Mind-Body Approach
The fundamental challenge in treating children with cancer centers on how to help relieve their suffering while they undergo difficult care. Typically, they do not yet have adult coping skills, and even if they had some ability to cope, many of the issues they face during treatment are...
Roberto Pili, MD, Expert in Prostate, Renal, and Bladder Cancers, Joins Indiana University Simon Cancer Center
Roberto Pili, MD, a nationally recognized expert in prostate, renal, and bladder cancers, has joined the Indiana University (IU) Melvin and Bren Simon Cancer Center. Dr. Pili is the Robert Wallace Miller Professor of Oncology at the Indiana University School of Medicine and Researcher at the IU...
ASCO Members, Public Working Together to ‘Take Down’ Cancer
From Wrigley Field to McCormick Place, Chicago residents and visitors felt the energy surrounding the launch of The Campaign to Conquer Cancer during the ASCO 2015 Annual Meeting. The Conquer Cancer Foundation of the American Society of Clinical Oncology (CCF) threw out the ceremonial first pitch...
Bert Vogelstein, MD, Receives 2015 Dr. Paul Janssen Award for Biomedical Research
Johnson & Johnson named Bert Vogelstein, MD, of Johns Hopkins University, Johns Hopkins Kimmel Cancer Center, and the Howard Hughes Medical Institute, the winner of the 2015 Dr. Paul Janssen Award for Biomedical Research for his breakthroughs in oncology research, which have spanned more than 2 ...
Pembrolizumab in Advanced NSCLC: The Promise of Immune Checkpoint Inhibitors
Drugs targeting the immune-checkpoint pathways have shown promising activity in non–small cell lung cancer (NSCLC). In a recent article in The New England Journal of Medicine, Garon and colleagues reported the results of the KEYNOTE-001 clinical trial evaluating single-agent pembrolizumab...
PD-1 Inhibitor Pembrolizumab Active in Advanced NSCLC: Outcomes Better With Higher PD-L1 Expression
In the phase I KEYNOTE-001 trial reported in The New England Journal of Medicine,1 Edward B. Garon, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, and colleagues found that the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab (Keytruda)...
Predicting Recurrence After Surgery in Renal Cell Carcinoma: 16-Gene Assay Recurrence Score Ushers in New Era
In a study reported in The Lancet Oncology and reviewed in this issue of The ASCO Post, Brian Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, and colleagues showed that a 16-gene assay recurrence score could predict postoperative outcome in patients with stage I to III clear cell renal...
Assessing and Improving Imaging Interpretation in Breast Cancer Screening
The quality of mammography images has markedly improved over the past few decades. However, the quality of the interpretation of mammograms remains variable. That said, more than 38 million mammograms are performed annually in the United States. So said Diana Buist, PhD, Senior Scientific...
Oncolytic Immunotherapy in Melanoma: It’s Not All About PD-1
The benefit from immune-directed therapies in patients with advanced melanoma is not limited to the exploding field of checkpoint inhibitors. According to Robert Andtbacka, MD, Associate Professor of Surgical Oncology, at the Huntsman Cancer Institute at the University of Utah, Salt Lake City,...
Poliovirus for Glioblastoma Grabs National Attention
Researchers at The Preston Robert Tisch Brain Tumor Center at Duke University are being barraged by patients wishing to enroll in their clinical trial of an engineered poliovirus for recurrent glioblastoma. This comes as a result of a CBS 60 Minutes interview with lead researcher Matthias...
Cost of Immunotherapy Projected to Top $1 Million per Patient per Year
If new immunotherapy combinations were administered to the half a million Americans dying of cancer each year, the nation’s price tag for treating them—for just 1 year—could top $174 billion, according to projections by Leonard Saltz, MD, Chief of Gastrointestinal Oncology and Chair of the Pharmacy ...
Expert Point of View: Sumanta K. Pal, MD
This combination [lenvatinib and everolimus] is a potential game-changer in metastatic renal cell carcinoma. We’ve studied other combinations to no avail; for example, bevacizumab [Avastin] plus everolimus had no advantage over everolimus alone. Other combinations are too toxic, such as sunitinib...
Lenvatinib/Everolimus: Robust Combination in Metastatic Renal Cell Carcinoma
The combination of lenvatinib (Lenvima) plus everolimus (Afinitor) significantly extended progression-free survival compared with everolimus alone in metastatic renal cell carcinoma, according to a randomized phase II trial.1 Median progression-free survival for patients who received the...
Expert Point of View: Anees B. Chagpar, MD
“This is an important study. We’ve known for some time that the aromatase inhibitors tend to be better than tamoxifen for postmenopausal women with hormonally sensitive invasive breast cancer. The NSABP B-35 trial asked the same question in ductal carcinoma in situ. These data, which now follow...
Anastrozole and Tamoxifen: Both Options for Ductal Carcinoma in Situ
Anastrozole was found to be at least as safe and effective as tamoxifen in preventing breast cancer recurrence in women with ductal carcinoma in situ, in the large NSABP B-35/SWOG-35 study.1 Among all women in the trial, however, the 10-year breast cancer–free interval rates were higher in women...
Expert Point of View: Shanu Modi, MD
Study discussant Shanu Modi, MD, of Memorial Sloan Kettering Cancer Center, New York, commented, “Neither T-DM1 [Kadcyla] nor T-DM1 plus pertuzumab [Perjeta] proved to be superior to the old standard of care, taxane plus trastuzumab [Herceptin]. MARIANNE was a valiant trial, but THP (taxane,...
How CancerLinQ™ Can Benefit People Living With Cancer
As a regular readers of The ASCO Post know, ASCO is developing an exciting new health information learning system called CancerLinQ™, which will exponentially enlarge our understanding of cancer therapy far beyond what we’ve achieved with our system of clinical trials. Cancer clinical trials have...
Biosimilars: Questions Remain
Biosimilars are biologic drugs that are similar to an already established “reference” or “innovator” biologic drug product and can be manufactured when an original biologic drug product’s patent expires. Reference to the innovator product is an integral component of approval for a biosimilar. The...
Expert Point of View: Michael P. Link, MD
“We have had remarkable success in treating patients with cancer. Millions of survivors are a testament to this success. But the ‘cost of cure’ borne by our patients is substantial in terms of diminished quality and quantity of life,” commented the formal discussant of the study Michael P. Link,...
Thyroid Cancer Rarely Diagnosed in Those With Asymptomatic, Benign Nodules
A prospective, multicenter, observational study involving 992 consecutive patients with one to four asymptomatic, sonographically or cytologically benign thyroid nodules found that “the majority of nodules exhibited no significant size change during 5 years of follow-up or actually decreased in...
Irwin Rose, PhD, Nobel Laureate and Biochemist, Dies at 88
Scientist and Nobel Laureate Irwin “Ernie” Rose, PhD, passed away June 2, 2015, after a long illness. He was 88. Dr. Rose shared the 2004 Nobel Prize for chemistry with Aaron Ciechanover, MD, DSc, and Avram Hershko, MD, PhD, of the Israel Institute of Technology for their pioneering work in...
2015 Oncology Meetings
JULY APOS 12th Annual Conference and IPOS 17th World Congress of Psycho-OncologyJuly 28–August 1 • Washington, DC For more information: http://www.apos-society.org/professionals/meetings-ed/annualconference.aspx 16th Annual International Lung Cancer Congress®July 30-August 1 • Huntington Beach,...
Expect Questions About Preventing Melanoma
A recent report from the Centers for Disease Control and Prevention (CDC) stated that the incidence of melanoma “doubled between 1982 and 2011, but comprehensive skin cancer prevention programs could prevent 20% of new cases between 2020 and 2030.”1,2 That report should serve to increase interest...
Capitalizing on Increased Interest in Skin Cancer During Summer to Reeducate People About Sunscreens and ‘Smart Sun Strategies’
Amid the encouraging studies reported at the 2015 ASCO Annual Meeting about advances in the treatment of melanoma was a troubling finding about the incidence of melanoma increasing. An analysis of data from nine Surveillance, Epidemiology, and End Results (SEER) registries found that the incidence...
Adjuvant Ipilimumab in High-Risk Stage III Melanoma: Encouraging Study Results Yet Questions Remain
Ipilimumab (Yervoy) is a fully human monoclonal antibody that blocks the negative T-cell regulator cytotoxic T-lymphocyte antigen 4 (CTLA-4) and has improved overall survival for patients with unresectable or metastatic melanoma in two phase III studies.1,2 Based upon these results, ipilimumab was...
American Ginseng
The use of dietary supplements by patients with cancer has increased significantly over the past 20 years despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and the ...
Memorial Sloan Kettering Cancer Center Receives Gift of $150 Million From David H. Koch
Memorial Sloan Kettering Cancer Center (MSK) announced that it has received the largest gift in its history, a commitment of $150 million, from long-time MSK board member David H. Koch. This unprecedented contribution will fund a state-of-the-art outpatient medical facility to be known as The David ...
FDA’s Pregnancy Category Labeling
INSIDE THE BLACK BOX is an occasional column providing insight into the U.S. Food and Drug Administration (FDA) and its policies and procedures. In this installment, FDA supervisory toxicologist Todd Palmby, PhD, and pharmacologist Eias Zahalka, PhD, MBA, discuss the approach taken in the Office of ...
David Gius, MD, PhD, Named Co-leader of Northwestern’s Women’s Cancer Research Program
David Gius, MD, PhD, has been named Co-leader of the Women’s Cancer Research Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, a position he has served in interim since February 2014. Dr. Gius, a nationally recognized radiation oncologist and researcher, is a...
John A. Zaia, MD, Named Director of Center for Gene Therapy at City of Hope
Gene therapy pioneer John A. Zaia, MD, has been named Director of the Center for Gene Therapy within City of Hope’s Hematologic Malignancies and Stem Cell Transplantation Institute. Internationally known and respected for his groundbreaking research into potential gene therapy treatments for HIV,...
Matthew Trunnell Named Vice President and Chief Information Officer at Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center announced the appointment of Matthew Trunnell as its Vice President and Chief Information Officer (CIO). Mr. Trunnell has worked at the intersection of information technology and life sciences research in both academic and commercial environments in support of ...
Gynecologic Cancer in the Older Patient: The Activities of the Elderly Working Group of NRG Oncology
Geriatrics for the Oncologist is guest edited by Stuart Lichtman, MD, FACP, FASCO, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Visit SIOG.org for more on geriatric oncology. The elderly population in the United States is growing, and by the year...
Comprehensive Oncology Practice Business Guide Now Available
ASCO has released Practical Tips for the Oncology Practice 6th Edition, a comprehensive business and management resource for oncology practices. Recognizing the increasing burdens that oncology practices face in today’s healthcare delivery system, ASCO is releasing this guide with new information...
2015 Palliative Care in Oncology Symposium to Highlight the Science of Symptom Management
For the past few decades, ASCO has led efforts to integrate palliative care into all phases of cancer treatment. Through numerous educational programs, advocacy efforts, and most recently, the first annual Palliative Care in Oncology Symposium, ASCO has championed the idea that palliative care,...
Progress in the Treatment of Patients With EGFR-Mutated NSCLC
Approximately 10% to 15% of patients with advanced non–small cell lung (NSCLC) cancer have mutations in the epidermal growth factor receptor (EGFR) in tumor cells. Specific therapies to inhibit the activity of EGFR-mutated NSCLC have now been clearly shown to improve response rate and...
Early-Phase Studies Show Activity of Novel EGFR Inhibitors Rociletinib and AZD9291 in T790M-Positive NSCLC
Two early-phase studies have shown that the novel epidermal growth factor receptor (EGFR) inhibitors rociletinib and AZD9291 exhibit high activity in non–small cell lung cancer (NSCLC) patients with the EGFR T790M mutation who had progressed on prior EGFR inhibitor therapy.1,2 The T790M mutation...
NCCS Advocates for Legislation to Establish Medicare Service for Cancer Survivorship Care Planning
Some years after successful treatment of a childhood cancer, a 16-year-old survivor required surgery to replace both hip joints, which were damaged from therapy containing steroids. An x-ray of the teenager’s destroyed joints is a stark reminder of the serious health challenges faced by cancer...
New Appointments Announced at Taussig Cancer Institute
The following new appointments were recently announced at Cleveland Clinic’s Taussig Cancer Institute. James Stevenson, MD Dr. Stevenson has been appointed Vice Chairman of the Department of Hematology and Medical Oncology. As Vice Chairman, Dr. Stevenson will assist the Chairman and Department...
Precision Medicine Trials Bring Targeted Treatments to More Patients
At the 2015 ASCO Annual Meeting, both ASCO and the National Cancer Institute (NCI) unveiled details of new precision medicine trials that will greatly expand the number of patients with cancer who are benefiting from targeted agents. The trials will match a patient’s tumor molecular profile with an ...
Expert Point of View: Daniel G. Coit, MD
Daniel G. Coit, MD, of Memorial Sloan Kettering Cancer Center, New York, and Chair of the National Comprehensive Cancer Network (NCCN) Melanoma Guidelines Panel, discussed the findings reported by Lewin et al at the ASCO Annual Meeting. “This is a small retrospective study examining a prospective...
PET/CT Detects Asymptomatic Melanoma Recurrences
In monitoring patients with melanoma at high risk for relapse, surveillance imaging with 18F-fluorodeoxyglucose–positron-emission tomography (FDG-PET)/computed tomography (CT) can detect asymptomatic metastases and thus facilitate early treatment, according to Australian investigators who presented ...
Expert Point of View: Wendy Stock, MD
Wendy Stock, MD, of the University of Chicago, was the formal discussant of these three studies presented at the 2015 ASCO Annual Meeting. Commenting on the first study on acute myeloid leukemia (AML) by Dr. Gerber and colleagues, she said, “This work can improve understanding of the leukemia stem...
Advancing Classification and Risk Stratification for Leukemia and Myelodysplastic Syndromes
Refinements in the classification and risk stratification for leukemia and myelodysplastic syndromes were reported by three different investigators at the 2015 ASCO Annual Meeting. The first study showed that leukemia stem cell phenotypes are associated with outcomes in acute myeloid leukemia...
New Concept for Brain Tumors: Tumor Treating Fields
A novel treatment modality that applies electric forces to brain tumors via scalp electrodes improved outcomes in a study reported at the 2015 ASCO Annual Meeting.1 In the first report of the full dataset, tumor treating fields significantly and consistently prolonged both progression-free...
Kevin Fitzpatrick Named CEO of CancerLinQ LLC
Kevin Fitzpatrick has been named CEO of CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO. Mr. Fitzpatrick, who is currently the Executive Vice President and Chief Innovation Officer of the American College of Cardiology (ACC), will begin his new role on August 3. CancerLinQ LLC was...
Expert Point of View: Kenneth Yu, MD, MSc
Kenneth Yu, MD, MSc, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, called investigational PEGPH20 “a very promising tumor microenvironment-targeted approach” that appears to be well tolerated. “The results are preliminary but there appears to be a biomarker ...
Expert Point of View: Noah Hahn, MD
Commenting on the pembrolizumab (Keytruda) phase Ib study, Noah Hahn, MD, of Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, called the overall response rate of 28% with pembrolizumab “pretty impressive. Nearly two-thirds of patients had some response or tumor reduction, and overall survival...
Immunotherapy Marches On, Making Headway in Advanced Urothelial Bladder Cancer
Two immunotherapy agents show promise in preliminary studies of advanced urothelial bladder cancer: the anti–PD-1 (programmed cell death protein 1) antibody pembrolizumab (Keytruda) and the anti–PD-L1 (programmed cell death ligand 1) antibody atezolizumab. Separate phase I studies of each drug...
Expert Point of View: Jeffrey L. Wolf, MD
Jeffrey L. Wolf, MD, Director of the Myeloma Program at the University of California, San Francisco, formally discussed the ENDEAVOR study at the ASCO Annual Meeting. He commented that the “doubling” in progression-free survival is “impressive” and said that “time will tell if this difference...
